Frontiers in Medicine 2022 April 13 [Link] Marcelo Luiz Balancin, Camila Machado Baldavira, Tabatha Gutierrez Prieto, Juliana Machado-Rugolo, CecĂ­lia Farhat, Aline Kawassaki Assato, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Alexandre Muxfeldt Ab’Saber, Teresa Yae Takagaki, Vera Luiza Capelozzi Abstract Background: Malignant pleural mesotheliomas (MM) are known for their heterogenous histology and clinical behavior. MM…

Read More

The Journal of Surgical Research 2022 April 27 [Link] Victor P Gazivoda, Aaron W Kangas-Dick, Alissa A Greenbaum, Joshua Roshal, Chunxia Chen, Dirk F Moore, Russell C Langan, Timothy J Kennedy, Christine Minerowicz, H Richard Alexander Abstract Introduction: Frequency of PD-L1 expression and the role of immunotherapy in malignant peritoneal mesothelioma (MPM) have not been…

Read More

Virchows Archiv 2022 April 24 [Link] Francesca Napoli, Ida Rapa, Stefania Izzo, Angelica Rigutto, Roberta Libener, Chiara Riganti, Paolo Bironzo, Riccardo Taulli, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract The standard front-line treatment for pleural mesothelioma (PM) is pemetrexed-based chemotherapy, whose major target is thymidylate synthase (TS). In several cancer models, miR-215 and…

Read More

Lung Cancer 2022 March 19 [Link] Ludovic Fournel, Thomas Charrier, Maxime Huriet, Amedeo Iaffaldano, Audrey Lupo, Diane Damotte, Jennifer Arrondeau, Marco Alifano Abstract Background: Prediction of prognosis is a key step of malignant pleural mesothelioma (MPM) management and treatment assignment. Aim of this study was to identify simple prognostic factors, focusing on inflammation-related parameters. Methods:…

Read More

Lung Cancer 2022 March 19 [Link] Ludovic Fournel, Thomas Charrier, Maxime Huriet, Amedeo Iaffaldano, Audrey Lupo, Diane Damotte, Jennifer Arrondeau, Marco Alifano Abstract Background: Prediction of prognosis is a key step of malignant pleural mesothelioma (MPM) management and treatment assignment. Aim of this study was to identify simple prognostic factors, focusing on inflammation-related parameters. Methods:…

Read More

American Journal of Clinical Pathology 2022 March 14 [Link] Raghavendra Pillappa, Austin Wiles, Sadia Sayeed, Valentina Robila Abstract Objectives: To examine the potential of cyclin D1/podoplanin dual immunohistochemical stain to differentiate malignant mesothelioma from reactive mesothelial proliferations. Methods: Cyclin D1/podoplanin dual immunohistochemistry was performed on 34 surgical cases of reactive mesothelial proliferations, malignant mesothelioma, and…

Read More

Lung Cancer 2022 February [Link] Samuel G Armato, Anna K Nowak, Roslyn J Francis, Sharyn I Katz, Manizha Kholmatov, Kevin G Blyth, Eyjolfur Gudmundsson, Andrew C Kidd, Ritu R Gill Abstract Imaging of mesothelioma plays a role in all aspects of patient management, including disease detection, staging, evaluation of treatment options, response assessment, pre-surgical evaluation,…

Read More

Epigenomes 2021 December 14 [Link] Maria Fortunata Lofiego, Sara Cannito, Carolina Fazio, Francesca Piazzini, Ornella Cutaia, Laura Solmonese, Francesco Marzani, Carla Chiarucci, Anna Maria Di Giacomo, Luana Calabrò, Sandra Coral, Michele Maio, Alessia Covre Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a severe prognosis, and with a long-standing need for more effective…

Read More

The American Journal of Surgical Pathology 2021 December 15 [Link] Talia L Fuchs, Angela Chou, Yagiz Aksoy, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa Ahadi, Anthony J Gill Abstract Although there is early support for schemes based on nuclear grade, necrosis and mitotic rate, there is currently no widely implemented grading system for diffuse pleural…

Read More

Journal for Immunotherapy of Cancer 2021 October [Link] Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto Abstract Background: JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM). Patients and methods:…

Read More